circulating tumor DNA (ctDNA)
DNA fragments shed by cancer cells into the bloodstream that can be detected and sequenced to identify cancer presence, tumor type, and genetic mutations
As defined in How early cancer screening can save lives | Peter Attia & Keith Flaherty
Where it comes up · 1
Most important claims · 9 of 9Search all claims for “circulating tumor DNA (ctDNA)” →
- Methods for detecting circulating tumor DNA are now being commercialized and can identify cancers across a broad array of cancer types (pan-cancer tests) far earlier than traditional imaging, with 10-100x more sensitive methods in R&D that will further improve detection capability.How early cancer screening can save lives | Peter Attia & Keith Flaherty
- Some cancers detected via circulating tumor DNA have targetable mutations for which effective drugs or immunotherapies exist, allowing treatment of microscopic disease before it becomes clinically manifest, even when imaging cannot localize the tumor.How early cancer screening can save lives | Peter Attia & Keith Flaherty
- Circulating tumor DNA can be analyzed not just for mutation sequences but also for methylation patterns—molecular folding/unfolding modifications—that indicate the cell type origin, allowing inference of cancer type even without imaging localization (e.g., methylation pattern of colon epithelial cells indicates colon cancer).How early cancer screening can save lives | Peter Attia & Keith Flaherty
- The fundamental clinical problem with using circulating tumor DNA to detect early-stage cancers is identifying the anatomical location and directing surgical intervention when you have only circulating DNA evidence but no imaging confirmation of a localized tumor.How early cancer screening can save lives | Peter Attia & Keith Flaherty
- There are two major clinical applications for circulating tumor DNA: (1) post-surgical surveillance to determine which patients still have microscopic residual disease and therefore need adjuvant therapy, and (2) pre-clinical detection of cancer at microscopic stages before any clinical manifestation.How early cancer screening can save lives | Peter Attia & Keith Flaherty
- Post-surgical circulating tumor DNA monitoring is easier than pre-clinical detection because after surgery you know exactly how the patient's specific cancer differs from normal cells, making it simpler to look for residual disease than to prospectively detect unknown early cancers.How early cancer screening can save lives | Peter Attia & Keith Flaherty
- When circulating tumor DNA is positive for a specific cancer type (inferred via methylation analysis) but imaging cannot yet localize the tumor, subsequent focused surveillance with directed imaging can detect the cancer at much earlier stages than traditional methods, even if detection takes 6-18 months of surveillance.How early cancer screening can save lives | Peter Attia & Keith Flaherty
- Post-treatment circulating tumor DNA monitoring becomes the 'most elegant way' for surveillance after surgery because you have a characterized reference tumor and are simply looking for its recurrence rather than prospectively seeking unknown disease.How early cancer screening can save lives | Peter Attia & Keith Flaherty
- There has been substantial investment and commercial scale-up of circulating tumor DNA technologies, indicating the field is moving rapidly from research methods (4 years ago) to clinically deployed and commercialized applications.How early cancer screening can save lives | Peter Attia & Keith Flaherty